Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials

Clinical Infectious Diseases

Volumn 42, Issue 6, 2006, Pages 870-877

  Raffi, François ^a   Katlama, Christine ^b   Saag, Michael ^c   Wilkinson, Martin ^f   Chung, Jain ^e   Smiley, Lynn ^d   Salgo, Miklos ^e  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Trimeris Inc   (United States)

^e HOFFMANN LA ROCHE INC   (United States)

^f ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ENFUVIRTIDE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG CROSS REACTIVITY; DRUG DOSE REGIMEN; EARLY VIROLOGICAL RESPONSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LONG TERM CARE; NONHUMAN; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD;

CLINICAL TRIALS, PHASE III; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33644834760     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/500206     Document Type: Article

References (21)

1. Cooper DA, Lange JM. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development. Lancet Infect Dis 2004; 4:426-36.
2. Arasteh K, Lazzarin A, Clotet B, et al. TORO: 96 - Week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen [abstract MoOrB1058]. In: Program and abstracts of the XV International AIDS Conference (Bangkok, Thailand). 2004:26.
3. Katlama C, Arastéh K, Clotet B, et al. Enfuvirtide TORO studies: 48-week results confirm 24-week findings [abstract LB2]. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment (Paris, France). 2003:280.
4. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85.
5. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-95.
6. Bartlett JA, Salgo M, DeMasi R. Early viral load responses on enfuvirtide in heavily treatment-experienced patients [abstract TuPeB4484]. In: Program and abstracts of the XV International AIDS Conference (Bangkok, Thailand). 2004:342.
7. Montaner J, DeMasi R, Delehanty J, Chung J, Gafoor Z, Salgo M. Analysis of virological response of enfuvirtide in TORO: implications for patient management. Antivir Ther 2003; 8(Suppl 1):S212.
8. Montaner J, Chung I, Guimaraes D, DeMasi R, Gafoor Z, Salgo M. A treatment staging proposal derived from a post hoc analysis of the 48-week results from the TORO studies [abstract TuPeB4483]. In: Program and abstracts of the XV International AIDS Conference (Bangkok, Thailand). 2004:342.
9. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004; 18:1137-46.
10. Huang W, De Gruttola V, Fischl M, et al. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. J Infect Dis 2001; 183:1455-65.
11. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13:1873-80.
12. Lepri AC, Miller V, Phillips AN, Rabenau H, Sabin CA, Staszewski S. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pretherapy viral load and the weeks 4-8 viral load. AIDS 2001; 15:47-54.
13. Mueller BU, Zeichner SL, Kuznetsov VA, Heath-Chiozzi M, Pizzo PA, Dimitrov DS. Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological, and pharmacological parameters measured during the first week under therapy. AIDS 1998; 12:F191-6.
14. Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001; 358:1760-5.
15. Mittler J, Essunger P, Yuen GJ, Clendeninn N, Markowitz M, Perelson AS. Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother 2001; 45:1438-43.
16. Smith CJ, Staszewski S, Sabin CA, et al. Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals. J Acquir Immune Defic Syndr 2004; 37:1155-9.
17. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2005; 4-5. Available at: http://www.aidsinfo.nih.gov/guidelines. Accessed 10 August 2005.
18. + cell increase to highly active antiretroviral therapy (HAART) at one year is predictive of clinical outcome despite incomplete viral suppression [abstract 144]. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment (Paris, France). 2003:S218.
19. + cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. J Infect Dis 2005; 192:1407-11.
20. Clumeck N, Cohen C, Thompson M, Molina JM, Wintfeld N, Green J. Relationship of undetectable viral load, change in CD4 count and enfuvirtide treatment on health-related quality of life [abstract P102]. In: Program and abstracts of the 7th International Congress on Drug Therapy in HIV Infection (Glasgow, United Kingdom). 2004:42.
21. Cohen C, Green J, Wintfeld N, Patel K. Patient acceptance with self-injection of enfuvirtide (ENF) for HIV over 48 weeks of treatment [abstract 7.1/1]. In: Program and abstracts of the 9th European AIDS Conference (Warsaw, Poland). 2003:46.